Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL

We report 101,326 single cell transcriptomes and surface protein landscape from the Chimeric antigen receptor-modified (CAR) T infusion products of 12 pediatric ALL patients upon CAR antigen-specific stimulation in comparison with TCR-mediated activation and controls. Overall design: By combining scRNA-seq and CITE-seq, CAR T cells in infusion products were analyzed upon CARspecific stimulation with human CD19-expressing antigen presenting cells (APCs), and compared them to 3 additional conditions: TCR-mediated stimulation, non-target APC stimulation, and unstimulated controls